h.norgaard
Submits third-party assay reports on material purchased directly. Based in Graz.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
9
n=9
Annotations
0
n=0
Median purity submitted
99.16%
n=9
Suppliers covered
7
n=9
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041977 | Humanin (HNG) | TFC | TFC-2605-U5564 | Medutest | 2026-Q3 | 99.19 | 6.76 | 103.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043003 | Tirzepatide | KP | KP-2602-X5446 | Nordanalyt | 2026-Q2 | 99.16 | 6.93 | 105.6 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041580 | CJC-1295 with DAC | QSC | QSC-2512-G6894 | Nordanalyt | 2026-Q1 | 98.85 | 2.69 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041512 | Enclomiphene citrate | QYB | QYB-2603-A6476 | Janoshik | 2026-Q1 | 99.23 | 5.11 | — | Supplier-supplied | 1 | FAIL |
| AX-2025-018455 | Semaglutide | WWB | WWB-2507-V2845 | Janoshik | 2025-Q4 | 99.05 | 4.91 | — | Supplier-supplied | 0 | PASS |
| AX-2025-020441 | CJC-1295 (no DAC) | KP | KP-2411-Y4921 | Medutest | 2024-Q4 | 99.59 | 3.94 | 94.9 | Supplier-supplied | 2 | MARGINAL |
| AX-2024-004372 | Retatrutide | QSC | QSC-2404-P8297 | VendorInvestigate | 2024-Q2 | 98.78 | 5.90 | — | Buyer-sourced | 3 | MARGINAL |
| AX-2024-004533 | SS-31 (Elamipretide) | JEEP | JEEP-2403-M2917 | PeptideMeter | 2024-Q2 | 99.72 | 2.73 | — | Supplier-supplied | 0 | PASS |
| AX-2024-005472 | Semaglutide | BCH | BCH-2405-U6438 | Janoshik | 2024-Q2 | 97.96 | 4.31 | 90.5 | Supplier-supplied | 2 | MARGINAL |